Document is current
Any future updates will be listed below
-
Authors
Carbone, Carmine https://orcid.org/0000-0001-5168-747X
De Luca, Roberto
Puca, Emanuele
Agostini, Antonio
Caggiano, Alessia
Priori, Lorenzo
Esposito, Annachiara
Ascrizzi, Serena
Piro, Geny
Salvatore, Lisa
De Sanctis, Francesco
Ugel, Stefano
Corbo, Vincenzo
Neri, Dario
Tortora, Giampaolo
- License Information
-
More Information
Article History
Received: 30 September 2024
Accepted: 24 November 2024
First Online: 7 January 2025
Declarations
:
: Animal experiments were approved by animal ethics committee of Catholic University of the Sacred Heart of Rome and by Ministry of Health with approval number n°593/2019-PR. This study was approved by the ethics committee of AOUI Verona Hospital (Territorial Ethics Committee for the South-West Veneto Area) with approval number Prot. n°53732. The patients provided written consent. This study was carried out in accordance with Declaration of Helsinki.
: All patients provided consent for publication.
: Dario Neri is a co-founder and shareholder of Philogen (), a Swiss-Italian Biotech company that operates in the field of ligand-based pharmacodelivery. Roberto De Luca, and Emanuele Puca are employees of Philochem AG, a daughter company of Philogen acting as discovery unit of the group.
